InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,265.56
(
0.28%
)
Post# of 252301
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 232755

Wednesday, 05/27/2020 6:06:20 PM

Wednesday, May 27, 2020 6:06:20 PM

Post# of 252301
IOVA—The clinical-data PR came first (4:01pm ET); the financing PR came second (4:20pm ET):

https://www.globenewswire.com/news-release/2020/05/27/2039716/0/en/Iovance-Reports-Pivotal-Cohort-4-Data-for-Tumor-Infiltrating-Lymphocyte-TIL-Therapy-Lifileucel-from-C-144-01-Clinical-Study-in-Advanced-Melanoma.html

https://www.globenewswire.com/news-release/2020/05/27/2039756/0/en/Iovance-Biotherapeutics-Inc-Announces-Proposed-Public-Offering-of-Common-Stock.html

Nevertheless, I concur that the timing of the two PRs is odd. Normally, companies allow investors more time for (purportedly) positive clinical data to sink in.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up